Novartis AG ADR (NVS)vsOccidental Petroleum Corporation (OXY)
NVS
Novartis AG ADR
$150.75
+1.44%
HEALTHCARE · Cap: $286.27B
OXY
Occidental Petroleum Corporation
$61.85
+0.98%
ENERGY · Cap: $60.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 162% more annual revenue ($56.67B vs $21.59B). NVS leads profitability with a 24.7% profit margin vs 10.8%. NVS appears more attractively valued with a PEG of 2.54. OXY earns a higher WallStSmart Score of 53/100 (C-).
NVS
Buy51
out of 100
Grade: C-
OXY
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-243.7%
Fair Value
$48.62
Current Price
$150.75
$102.13 premium
Margin of Safety
-414.6%
Fair Value
$9.18
Current Price
$61.85
$52.67 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Revenue surging 148.9% year-over-year
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.9B in free cash flow
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
ROE of 5.9% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : OXY
The strongest argument for OXY centers on Revenue Growth, Market Cap, Price/Book. Revenue growth of 148.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : OXY
The primary concerns for OXY are Return on Equity, Piotroski F-Score, PEG Ratio. A P/E of 45.4x leaves little room for execution misses.
Key Dynamics to Monitor
NVS profiles as a value stock while OXY is a growth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.50 — expect wider price swings.
OXY is growing revenue faster at 148.9% — sustainability is the question.
OXY generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
OXY scores higher overall (53/100 vs 51/100) and 148.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Occidental Petroleum Corporation
ENERGY · OIL & GAS E&P · USA
Occidental Petroleum Corporation is an American company engaged in hydrocarbon exploration in the United States, the Middle East, and Colombia as well as petrochemical manufacturing in the United States, Canada, and Chile.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?